A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 217, Issue 12, Pages -
Publisher
Rockefeller University Press
Online
2020-09-01
DOI
10.1084/jem.20191166
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
- (2020) Theodore L. Roth et al. CELL
- T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
- (2019) Tori N. Yamamoto et al. JOURNAL OF CLINICAL INVESTIGATION
- T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
- (2019) Aude G. Chapuis et al. NATURE MEDICINE
- Engineered adoptive T-cell therapy prolongs survival in a preclinical model of advanced stage ovarian cancer
- (2019) Kristin G. Anderson et al. Cancer Immunology Research
- T Cell Dysfunction in Cancer
- (2018) Daniela S. Thommen et al. CANCER CELL
- 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses
- (2018) Ashley V. Menk et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- CAR-T cells: the long and winding road to solid tumors
- (2018) Maria Michela D’Aloia et al. Cell Death & Disease
- Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation
- (2018) Alvaro Teijeira et al. Cancer Immunology Research
- Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism
- (2018) Jingjing Zhu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent
- (2017) Diogo Gomes-Silva et al. Cell Reports
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- 4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8+ T cell proliferation
- (2016) Beom K Choi et al. Cellular & Molecular Immunology
- Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy
- (2016) Alfonso R. Sanchez-Paulete et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Protein Translation Activity: A New Measure of Host Immune Cell Activation
- (2016) Mina O. Seedhom et al. JOURNAL OF IMMUNOLOGY
- Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul
- (2016) G. M. Delgoffe Cancer Immunology Research
- Role of IL-2 in cancer immunotherapy
- (2016) Tao Jiang et al. OncoImmunology
- T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma
- (2015) Ingunn M. Stromnes et al. CANCER CELL
- Erratum: The role of CD95 and CD95 ligand in cancer
- (2015) M E Peter et al. CELL DEATH AND DIFFERENTIATION
- Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy
- (2015) Sebastian Kobold et al. JNCI-Journal of the National Cancer Institute
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy
- (2015) Sebastian Kobold et al. JNCI-Journal of the National Cancer Institute
- Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD
- (2015) A. Kunkele et al. Cancer Immunology Research
- 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
- (2015) Todd Bartkowiak et al. Frontiers in Oncology
- Inactivation of the Transcription Factor GLI1 Accelerates Pancreatic Cancer Progression
- (2014) Lisa D. Mills et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Human B Cell-Derived Lymphoblastoid Cell Lines Constitutively Produce Fas Ligand and Secrete MHCII+FasL+ Killer Exosomes
- (2014) Matthew W. Klinker et al. Frontiers in Immunology
- Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
- (2013) Michael A. Curran et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity
- (2013) C. Ankri et al. JOURNAL OF IMMUNOLOGY
- 4-1BB Signaling Activates the T Cell Factor 1 Effector/β-Catenin Pathway with Delayed Kinetics via ERK Signaling and Delayed PI3K/AKT Activation to Promote the Proliferation of CD8+ T Cells
- (2013) Do Y. Lee et al. PLoS One
- Targeting the Fas/FasL signaling pathway in cancer therapy
- (2012) María Villa-Morales et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor
- (2012) Megan E. Prosser et al. MOLECULAR IMMUNOLOGY
- Mitochondrial Respiratory Capacity Is a Critical Regulator of CD8+ T Cell Memory Development
- (2011) Gerritje J.W. van der Windt et al. IMMUNITY
- Abrogating Cbl-b in effector CD8+ T cells improves the efficacy of adoptive therapy of leukemia in mice
- (2010) Ingunn M. Stromnes et al. JOURNAL OF CLINICAL INVESTIGATION
- Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand
- (2009) A. Wyzgol et al. JOURNAL OF IMMUNOLOGY
- Relationship between CD107a expression and cytotoxic activity
- (2008) Esin Aktas et al. CELLULAR IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started